NASDAQ:CUE

Cue Biopharma Stock Insider Trading

etoro logo Buy CUE
*Your capital is at risk
$30.73
+2.27 (+7.98%)
At Close: Jun 22, 2026

Cue Biopharma Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be positive at 100.00. In total, the insiders bought 14.48M and sold 0 CUE shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power

(Last 100 transactions)
100.00
Buy 14.48M shares
Sell 0 shares
100% Buy Activity
Negligible or No Correlation

No Significant Signals

No statistically significant buy or sell signals detected in recent insider data.

Historical Insider Trades

Date Type Person Role Amount
Jun 01, 2026
Buy
Stock Option (Right to Buy)
Ray Sumita
Chief Legal Compliance Officer
Officer 109 179
Value: $3.32M
Jun 01, 2026
Buy
Common Stock
Ray Sumita
Chief Legal Compliance Officer
Officer 0
Value: $0
Jun 01, 2026
Buy
Common Stock
J-Other
Meluzio Michael Vincent
Insider
Other 0
Value: $0
Jun 01, 2026
Buy
Pre-Funded Warrants (Right to Buy)
P-Purchase
Lin Shao-lee
Chief Executive Officer
CEO / President 90 906
Value: $91
Jun 01, 2026
Buy
Common Stock Warrants (Right to Buy)
P-Purchase
Lin Shao-lee
Chief Executive Officer
CEO / President 45 453
Value: $500.0K
May 30, 2026
Buy
Common Stock
J-Other
Camardo Daniel A.
Insider
Other 0
Value: $0
May 30, 2026
Buy
Stock Option (Right to Buy)
A-Award
Camardo Daniel A.
Director
Director 1 626
Value: $35.6K
May 30, 2026
Buy
Stock Option (Right to Buy)
A-Award
Meehan Viola Mong
Director
Director 1 626
Value: $35.6K
May 30, 2026
Buy
Common Stock
J-Other
Meehan Viola Mong
Insider
Other 0
Value: $0
May 03, 2026
Buy
Common Stock
A-Award
Lin Shao-lee
Chief Executive Officer
CEO / President 327 537
Value: $10.1M
May 03, 2026
Buy
Stock Option (right to buy)
A-Award
Lin Shao-lee
Chief Executive Officer
CEO / President 655 074
Value: $19.9M
Apr 30, 2026
Buy
Common Stock
J-Other
Lin Shao-lee
Insider
Other 0
Value: $0
Apr 09, 2026
Buy
Stock Option (right to buy)
A-Award
Warren Lucinda
Chief Business Officer
Officer 250 000
Value: $72.5K
Apr 09, 2026
Buy
Stock Option (right to buy)
A-Award
Sandercock Colin
SVP, General Counsel
Officer 200 000
Value: $58.0K
Apr 09, 2026
Buy
Stock Option (right to buy)
A-Award
Baker Daniel G.
Chief Development Officer
Officer 100 000
Value: $29.0K
Jan 02, 2026
Buy
Stock Option (right to buy)
A-Award
Sarraf Pasha
Director
Director 24 400
Value: $8K
Jan 02, 2026
Buy
Stock Option (right to buy)
A-Award
Verheyen Patrick
Director
Director 24 400
Value: $8K
Jan 02, 2026
Buy
Stock Option (right to buy)
A-Award
Morich Frank
Director
Director 24 400
Value: $8K
Jan 02, 2026
Buy
Stock Option (right to buy)
A-Award
Kiener Peter A
Director
Director 24 400
Value: $8K
Jan 02, 2026
Buy
Stock Option (right to buy)
A-Award
Broadfoot Jill Marie
Director
Director 24 400
Value: $8K
Jan 02, 2026
Buy
Stock Option (right to buy)
A-Award
Garzone Pamela
Director
Director 24 400
Value: $8K
Dec 30, 2025
Buy
Common Stock
P-Purchase
Sarraf Pasha
Director
Director 86 947
Value: $27.6K
Dec 30, 2025
Buy
Common Stock
P-Purchase
Sarraf Pasha
Director
Director 77 417
Value: $23.3K
Dec 30, 2025
Buy
Common Stock
P-Purchase
Sarraf Pasha
Director
Director 78 116
Value: $24.3K
Dec 30, 2025
Buy
Common Stock
P-Purchase
Sarraf Pasha
Director
Director 77 148
Value: $23.2K

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

Click to get the best stock tips daily for free!
ABOUT CUE BIOPHARMA INC.
Cue Biopharma
Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops biologic drugs for the selective modulation of the human immune system to treat a range of cancers, chronic infectious diseases, and autoimmune disorders. Its lead drug candidate is CUE-101, a fusion protein biologic that is in Phase 1b clinical trial designed to target and activate antigen-specific T cells for human papilloma virus-driven cancers. The company offers CUE-10...
GOLDEN STAR
Ticker Change Signal Date
IDYA
$28.98
18.12% Jun 12
DHI
$146.71
6.29% Jun 10
PHM
$118.49
6.02% Jun 10
EAT
$140.46
17.09% Jun 05
E
ETD
$20.67
3.19% Jun 05

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE